Core Industry Metrics

As part of our mission to be the industry’s go-to source for market data, we provide and update this repository of core pharmaceutical industry metrics free to interested parties. To download the raw data MS Excel sets, use the links below.

CRO Core Metrics   |   CMO Core Metrics   |   Other Core Industry Metrics

Excel sets last updated: April 2022 with data from Q4, 2021

*IQVIA (Quintiles) total gross revenue has been adjusted to the proportion related to R&D solutions. =0.647
PRA and ICON merged in July, 2021 – data will be combined going forward (Q3, 2021)

*Celltrion removed because financials include innovator drugs and CDMO services.

*Companies included: Viatris, Teva, Sun Pharmaceutical, Aurobindo, Lupin
**Innovator companies and companies with medical device offerings omitted from above rankings.

*Companies included: J&J, Pfizer, Roche, Novartis, Merck & Co., GlaxoSmithKline, Sanofi, AbbVie, Takeda, Shanghai Pharmaceuticals

Top 20 Drug Sales

Source: https://www.fiercepharma.com/special-report/top-20-drugs-by-2020-sales

No.
Drug Name
Active Ingredient
Approval Date
FDA-approved use on approval date*
1
Verquvo
vericiguat
1/19/21
To mitigate the risk of cardiovascular death and hospitalization for chronic heart failure
2
Cabenuva
cabotegravir and rilpivirine (co-packaged)
1/21/21
To treat HIV
3
Lupkynis
voclosporin
1/22/21
To treat lupus nephritis
4
Tepmetko
tepotinib
2/3/21
To treat non-small cell lung cancer
5
Ukoniq
umbralisib
2/5/21
To treat marginal zone lymphoma and follicular lymphoma
6
Evkeeza
evinacumab-dgnb
2/11/21
To treat homozygous familial hypercholesterolemia
7
Cosela
trilacicilib
2/12/21
To mitigate chemotherapy-induced myelosuppression in small cell lung cancer
8
Amondys 45
casimersen
2/25/21
To treat Duchenne muscular dystrophy
9
Nulibry
fosdenopterin
2/26/21
To reduce the risk of mortality in molybdenum cofactor deficiency Type A
10
Pepaxto
melphalan flufenamide
2/26/21
To treat relapsed or refractory multiple myeloma
11
Azstarys
serdexmethylphenidate and dexmethylphenidate
3/2/21
To treat attention deficit hyperactivity disorder
12
Fotivda
tivozanib
3/10/21
To treat renal cell carcinoma
13
Ponvory
ponesimod
3/18/21
To treat relapsing forms of multiple sclerosis
14
Zegalogue
dasiglucagon
3/22/21
To treat severe hypoglycemia
15
Qelbree
viloxazine
4/2/21
To treat attention deficit hyperactivity disorder
16
Nextstellis
drospirenone and estetrol
4/15/21
To prevent pregnancy
17
Jemperli
dostarlimab-gxly
4/22/21
To treat endometrial cancer
18
Zynlonta
loncastuximab tesirine-lpyl
4/23/21
To treat certain types of relapsed or refractory large B-cell lymphoma
19
Empaveli
pegcetacoplan
5/14/21
To treat paroxysmal nocturnal hemoglobinuria
20
Rybrevant
amivantamab-vmjw
5/21/21
To treat a subset of non-small cell lung cancer
21
Pylarify
piflufolastat F 18
5/26/21
To identify prostate-specific membrane antigen-positive lesions in prostate cancer
22
Lumakras
sotorasib
5/28/21
To treat types of non-small cell lung cancer
23
Truseltiq
infigratinib
5/28/21
To treat cholangiocarcinoma whose disease meets certain criteria
24
Lybalvi
olanzapine and samidorphan
5/28/21
To treat schizophrenia and certain aspects of bipolar I disorder
25
Brexafemme
ibrexafungerp
6/1/21
To treat vulvovaginal candidiasis
26
Aduhelm
aducanumab-avwa
6/7/21
To treat Alzheimer’s disease
27
Rylaze
asparaginase erwinia chrysanthemi (recombinant)-rywn
6/30/21
To treat acute lymphoblastic leukemia and lymphoblastic lymphoma in patients who are allergic to E. coli-derived asparaginase products, as a component of a chemotherapy regimen
28
Kerendia
finerenone
7/9/21
To reduce the risk of kidney and heart complications in chronic kidney disease associated with type 2 diabetes
29
feinidazole
fexinidazole
7/16/21
To treat human African trypanosomiasis caused by the parasite Trypanosoma brucei gambiense
30
Rezurock
belumosudil
7/16/21
To treat chronic graft-versus-host disease after failure of at least two prior lines of systemic therapy
31
Bylvay
odevixibat
7/20/21
To treat pruritus
32
Saphnelo
anifrolumab-fnia
7/30/21
To treat moderate-to severe systemic lupus erythematousus along with standard therapy
33
Nexviazyme
avalglucosidase alfa-ngpt
8/6/21
To treat late-onset Pompe disease
34
Welireg
belzutifan
8/13/21
To treat von Hippel-Lindau disease under certain conditions
35
Korsuva
difelikefalin
8/23/21
To treat moderate-to-severe pruritus associated with chronic kidney disease in certain populations
36
Skytofa
lonapegsomatropin-tcgd
8/25/21
To treat short stature due to inadequate secretion of endogenous growth hormone
37
Exkivity
mobocertinib
9/15/21
To treat locally advanced or metastatic non-small cell lung cancer with epidermal growth factor receptor exon 20 insertion mutations
38
Tivdak
tisotumab vedotin-tftv
9/20/21
To treat recurrent or metastatic cervical cancer with disease progression on or after chemotherapy
39
Qulipta
atogepant
9/28/21
To prevent episodic migraines
40
Livmarli
maralixibat
9/29/21
To treat cholestatic pruritus associated with Alagille syndrome
41
Tavneos
avacopan
10/7/21
To treat severe active anti-neutrophil cytoplasmic autoantibody-associated vasculitis (granulomatosis with polyangiitis and microscopic polyangiitis) in combination with standard therapy, including glucocorticoids
42
Scemblix
asciminib
10/29/21
To treat Philadelphia chromosome-positive chronic myeloid leukemia with disease that meets certain criteria
43
Besremi
ropeginterferon alfa-2b-njft
11/12/21
To treat polycythemia vera, a blood disease that causes the overproduction of red blood cells
44
Voxzogo
vosoritide
11/19/21
To improve growth in children five years of age and older with achondroplasia and open epiphyses
45
Livtencity
maribavir
11/23/21
To treat post-transplant cytomegalovirus (CMV) infection/disease that does not respond (with or without genetic mutations that cause resistance) to available antiviral treatment for CMV
46
Cytalux 
pafolacianine
11/29/21
To help identify ovarian cancer lesions 
47
Tezspire
tezepelumab-ekko
12/17/21
To treat severe asthma as an add-on maintenance therapy 
48
Vyvgart
efgartigimod alfa-fcab
12/17/21
To treat generalized myasthenia gravis
49
Legvio
inclisiran
12/22/21
To treat heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease as an add-on therapy
50
Adbry
tralokinumab-ldrm
12/27/21
To treat moderate-to-severe atopic dermatitis 

Core Industry Metrics Updates

Sign up to receive a notification when we update our Core Pharmaceutical Industry Metrics.